|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.640 USD | -1.89% |
|
+8.66% | +81.09% |
| 08:32am | Opus Genetics Completes Enrollment in Phase 3 Gene Therapy Trial for Rare Blindness Disorder | MT |
| 07-29 | TD Cowen Initiates Opus Genetics at Buy | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 306M | - | - | - | ||
| 1,024B | |||||
| 618B | |||||
| 443B | |||||
| 349B | |||||
| 297B |
- Stock Market
- Stocks
- IRD Stock
- Charts Opus Genetics, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
